Report from Annual General Meeting

Report from Annual General Meeting

At Vitrolife's Annual General Meeting yesterday, April 29, the following,
amongst other things, was decided:

• No dividend will be paid for the financial year 2007. 

• Re-election of Board members Patrik Tigerschiöld, Fredrik Mattsson, Madeleine
Olsson-Eriksson and Semmy Rülf and new election of Tord Lendau and Maris
Hartmanis, in accordance with the election committee's proposal. 

• Authorization for the Board, for the time up until the next Annual General
Meeting and on one or more occasions, to take a decision on the issue of a
maximum of 1,950,000 shares in total, corresponding to approximately 9.8 percent
of the company's share capital. 

• The Board was authorized to take a decision, up until the next Annual General
Meeting and on one or more occasions, with regard to the acquisition and
transfer of the company's own shares, at the most 10 percent of the company's
shares. 

• The proposed principles for remuneration and other conditions of employment
for the senior management were approved.

• The Board's proposal for a resolution concerning warrants to subscribe for new
shares was approved. The warrants, maximum 400,000, are to be offered to
employees of the Vitrolife Group.


At the Board meeting following election which was held after the Annual General
Meeting, Patrik Tigerschiöld was elected Chairman of the Board.



April 30, 2008
Gothenburg, Sweden
The Board



Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is
required to publish in accordance with the Securities Exchange and Clearing
Operations Act.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.